Ipilimumab, Nivolumab, Tocilizumab and Radiation in Pretreated Patients With Advanced Pancreatic Cancer (TRIPPLE-R)
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT04258150 |
|
Recruitment Status :
Terminated
(primary endpoint was not met)
First Posted : February 6, 2020
Last Update Posted : March 31, 2022
|
Sponsor:
Herlev Hospital
Information provided by (Responsible Party):
Inna Chen, MD, Herlev Hospital
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
No Study Results Posted on ClinicalTrials.gov for this Study
| Recruitment Status : | Terminated |
|---|---|
| Actual Primary Completion Date : | November 23, 2021 |
| Actual Study Completion Date : | November 23, 2021 |